Deucravacitinib demonstrated significant improvements in patient-reported outcomes in phase II SLE trial
Subcutaneous Tocilizumab, Alone or with Methotrexate, Demonstrated Superior Efficacy Over Methotrexate Monotherapy in Chinese RA Patients
Deucravacitinib demonstrates broad minimal disease activity component improvements in psoriatic arthritis: Phase 2 trial results
Anifrolumab Shows Durable Benefits in Achieving LLDAS and Remission in SLE: TULIP and Extension Trial Outcomes
No association between abatacept exposure levels and infection risk in early RA: AVERT-2 trial findings
C-reactive protein-albumin-lymphocyte index identified as a promising biomarker for osteoarthritis risk
